Skip to search formSkip to main contentSkip to account menu

OPT 80

Known as: OPT-80, OPT80 cpd 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Glycosidesfidaxomicin
Tiacumicin B

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Fidaxomicin for the Treatment of Clostridium diffìcile Infections
Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile… 
Review
2011
Review
2011
Is OPT-80 a Safe and Effective Treatment for Patients with C.difficile Infection?
OBJECTIVE: Objective of this systematic review is to determine whether or not OPT-80 is a safe and effective treatment for… 
2010
2010
In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp
Fidaxomicin (formerly OPT-80) is a narrow-spectrum investigational, nonabsorbed oral agent being developed for the treatment of… 
Review
2010
Review
2010
Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection
Objective: To evaluate the efficacy and safety of fidaxomicin for the treatment of Clostridium difficile infection. Data Sources… 
Highly Cited
2008
Highly Cited
2008
Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
ABSTRACT OPT-80, a novel, minimally absorbed macrocycle, is a candidate treatment option for Clostridium difficile infection (CDI… 
Review
2008
Review
2008
OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review.
BACKGROUND Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… 
Review
2008
Review
2008
OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review
Background: Clostridium difficile-associated diarrhoea has become a major problem over the last years. Increasing incidence and… 
Review
2007
Review
2007
Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.
Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum… 
2006
2006
Mutation in the Bacillus subtilis RNA Polymerase β′ Subunit Confers Resistance to Lipiarmycin
Lipiarmycin (Lprm) (8), a macrocyclic antibiotic also known as tiacumicin (2), is currently under development under the name of… 
1961
1961
Erfahrungen der nachgehenden Wochenbettfürsorge
In den letzten 10 Jahren ist der Anteil der Klinikentbindungen an der Gesamtentbindungszahl stark angestiegen. Wir haben nur etwa… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)